ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7284-7290

  Carlomagno, Francesca ^a   Vitagliano, Donata ^a   Guida, Teresa ^a   Ciardiello, Fortunato ^a   Tortora, Giampaolo ^a   Vecchio, Giancarlo ^a   Ryan, Anderson J ^c   Fontanini, Gabriella ^b   Fusco, Alfredo ^a   Santoro, Massimo ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c ASTRAZENECA   (United Kingdom)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; FAMILIAL CANCER; GENE ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

3T3 CELLS; ANIMALS; CARCINOMA, PAPILLARY; CELL TRANSFORMATION, NEOPLASTIC; DROSOPHILA PROTEINS; ENZYME INHIBITORS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0037115405     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Manie, S., Santoro, M., Fusco, A., and Billaud, M. The RET receptor: Function in development and dysfunction in congenital malformation. Trends Genet., 17: 580-589, 2001.
2. Jhiang, S. M. The RET proto-oncogene in human cancers. Oncogene, 19: 5590-5597, 2000.
3. Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Porta, G., Fusco, A., and Vecchio, G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 60: 557-563, 1990.
4. Santoro, M., Dathan, N. A., Berlingieri, M. T., Bongarzone, I., Paulin, C., Grieco, M., Pierotti, M. A., Vecchio, G., and Fusco, A. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene, 9: 509-516, 1994.
5. Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H., and Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res., 57: 1690-1694, 1997.
6. Basolo, F., Giannini, R., Monaco, C., Melillo, R. M., Carlomagno, F., Pancrazi, M., Salvatore, G., Chiappetta, G., Pacini, F., Elisei, R., Miccoli, P., Pinchera, A., Fusco, A., and Santoro, M. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol., 160: 247-254, 2002.
7. Eng, C., Clayton, D., Schuffenecker, I., Lenoir, G., Cote, G., Gagel, R. F., van Amstel, H. K., Lips, C. J., Nishisho, I., Takai, S. I., Marsh, D. J., Robinson, B. G., Frank-Raue, K., Raue, F., Xue, F., Noll, W. W., Romei, C., Pacini, F., Fink, M., Niederle, B., Zedenius, J., Nordenskjold, M., Komminoth, P., Hendy, G. N., Mulligan, L. M., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA, 276: 1575-1579, 1996.
8. Ponder, B. A. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res., 59: 1736-1741, 1999.
9. Schilling, T., Burck, J., Sinn, H. P., Clemens, A., Otto, H. F., Hoppner, W., Herfarth, C., Ziegler, R., Schwab, M., and Raue, F. Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int. J. Cancer, 95: 62-66, 2001.
10. Rodrigues, G. A., and Park, M. Oncogenic activation of tyrosine kinases. Curr. Opin. Genet. Dev., 4: 15-24, 1994.
11. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (Wash. DC), 267: 381-383, 1995.
12. Zhou, S., Carraway, K. L., III, Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Eng, C., Lorenzo, M. J., Ponder, B. A. J., Mayer, B. J., and Cantley, L. C. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (Lond.), 373: 536-539, 1995.
13. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther., 82: 231-239, 1999.
14. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
15. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J. O., Musgrove, H. L., Graham, G. A., Hughes, G. D., Thomas, A. P., Stokes, E. S., Curry, B., Richmond, G. H., Wadsworth, P. F., Bigley, A. L., and Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 62: 4645-4655, 2002.
16. Di Fiore, P. P., Segatto, O., Taylor, W. G., Aaronson, S. A., and Pierce, J. H. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science (Wash. DC), 248: 79-83, 1990.
17. Santoro, M., Wong, W. T., Aroca, P., Santos, E., Matoskova, B., Grieco, M., Fusco, A., and di Fiore, P. P. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: Evidence for a ret-specific signaling pathway. Mol. Cell. Biol., 14: 663-675, 1994.
18. Fusco, A., Berlingieri, M. T., Di Fiore, P. P., Portella, G., Grieco, M., and Vecchio, G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol., 7: 3365-3370, 1987.
19. Ishizaka, Y., Ushijima, T., Sugimura, T., and Nagao, M. cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun., 168: 402-408, 1990.
20. Basolo, F., Giannini, R., Toniolo, A., Casalone, R., Nikiforova, M., Pacini, F., Elisei, R., Miccoli, P., Berti, P., Faviana, P., Fiore, L., Monaco, C., Pierantoni, G. M., Fedele, M., Nikiforov, Y. E., Santoro, M., and Fusco, A. Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int. J. Cancer, 97: 608-614, 2002.
21. Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., and Koeffler, H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Investig., 91, 179-184, 1993.
22. MacDonald, J. I., Verdi, J. M., and Meakin, S. O. Activity-dependent interaction of the intracellular domain of rat trkA with intermediate filament proteins, the β-6 proteasomal subunit. Ras-GRF1, and the p162 subunit of eIF3. J. Mol. Neurosci., 13: 141-158, 1999.
23. Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A., Gazit, A., Levitzki, A., and Santoro, M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res., 62: 1077-1082, 2002.
24. Fontanini, G., Faviana, P., Lucchi, M., Boldrini, L., Mussi, A., Camacci, T., Mariani, M. A., Angeletti, C. A., Basolo, F., Pingitore, R. A. high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer, 86: 558-563, 2002.
25. Folkman, J. Angiogenesis-dependent diseases. Semin. Oncol., 28: 536-542, 2001.
26. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
27. Fong, T. A., Shawyer, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
28. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Curwen, J. O., Hennequin, L. F., Thomas, A. P., Stokes, E. S., Curry, B., Richmond, G. H., and Wadsworth, P. F. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res., 60: 970-975, 2000.
29. Wells, S. A., Jr., and Franz, C. Medullary carcinoma of the thyroid gland. World J. Surg., 24: 952-956, 2000.